Related Experiment Videos
Changes in pancreatic function after pancreatoduodenectomy
N Sato1, K Yamaguchi, K Yokohata
1Department of Surgery I, Kyushu University Faculty of Medicine, Fukuoka, Japan.
American Journal of Surgery
|July 31, 1998
Summary
Pancreatoduodenectomy impacts pancreatic function differently for malignant versus benign conditions. Surgeons should monitor exocrine function post-periampullary cancer surgery and glucose metabolism after benign disease surgery.
Area of Science:
- Gastroenterology
- Surgical Oncology
- Endocrinology
Background:
- Pancreatic function alterations after pancreatoduodenectomy differ between malignant and benign diseases.
- Understanding these differences is crucial for patient management.
Purpose of the Study:
- To compare exocrine and endocrine pancreatic function changes after pancreatoduodenectomy in patients with malignant (periampullary cancer) versus benign pancreatic disorders.
Main Methods:
- 34 patients (18 malignant, 16 benign) underwent pancreatoduodenectomy.
- Exocrine and endocrine functions were assessed pre-surgery, short-term (<2 months), and long-term (>12 months) post-surgery.
- Assessments included BT-PABA test, fasting blood sugar, and oral glucose tolerance test.
Main Results:
- Malignant group: Short-term decrease, long-term recovery of urinary PABA excretion. Benign group: Long-term increase in PABA excretion without short-term decline.
- Preoperative diabetes was higher in the malignant group (61% vs. 38%).
- Glucose tolerance improved post-surgery in 55% of malignant patients, but only 17% of benign patients. New-onset diabetes occurred in 30% of benign patients with normal preoperative tolerance, but none in the malignant group.
Conclusions:
- Post-pancreatoduodenectomy, focus on exocrine pancreatic function in periampullary cancer patients.
- Monitor glucose metabolism in benign disease patients, especially short-term post-surgery.